Evonik Evonik

X

Find Motixafortide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Motixafortide
Also known as: Bl-8040, 4f-benzoyl-tn14003, Motixafortide [usan], Tf14016, Bkt140, Bkt 140
Molecular Formula
C97H144FN33O19S2
Molecular Weight
2159.5  g/mol
InChI Key
JJVZSYKFCOBILL-MKMRYRNGSA-N
FDA UNII
DA9G065962

Motixafortide is an orally bioavailable inhibitor of CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity. CXCR4 antagonist BL-8040 selectively binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor 1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. In addition, inhibition of CXCR4 may induce mobilization of hematopoietic cells from the bone marrow into blood. The G protein-coupled receptor CXCR4 plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; SDF-1/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.
1 2D Structure

Motixafortide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3S,6S,9S,12S,15R,20R,23S,26S,29S,32S)-3,6-bis(4-aminobutyl)-N-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]-15-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-5-carbamimidamido-2-[(4-fluorobenzoyl)amino]pentanoyl]amino]pentanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-26-(3-carbamimidamidopropyl)-9,23-bis[3-(carbamoylamino)propyl]-12,29-bis[(4-hydroxyphenyl)methyl]-2,5,8,11,14,22,25,28,31-nonaoxo-17,18-dithia-1,4,7,10,13,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-20-carboxamide
2.1.2 InChI
InChI=1S/C97H144FN33O19S2/c98-60-33-31-58(32-34-60)78(135)119-65(19-8-42-113-93(104)105)79(136)121-68(21-10-44-115-95(108)109)83(140)126-73(51-56-25-30-57-14-1-2-15-59(57)48-56)87(144)130-75-53-152-151-52-74(88(145)118-63(77(101)134)18-7-41-112-92(102)103)129-84(141)69(23-12-46-117-97(111)150)122-81(138)66(20-9-43-114-94(106)107)124-86(143)72(50-55-28-37-62(133)38-29-55)128-90(147)76-24-13-47-131(76)91(148)70(17-4-6-40-100)125-82(139)64(16-3-5-39-99)120-80(137)67(22-11-45-116-96(110)149)123-85(142)71(127-89(75)146)49-54-26-35-61(132)36-27-54/h1-2,14-15,25-38,48,63-76,132-133H,3-13,16-24,39-47,49-53,99-100H2,(H2,101,134)(H,118,145)(H,119,135)(H,120,137)(H,121,136)(H,122,138)(H,123,142)(H,124,143)(H,125,139)(H,126,140)(H,127,146)(H,128,147)(H,129,141)(H,130,144)(H4,102,103,112)(H4,104,105,113)(H4,106,107,114)(H4,108,109,115)(H3,110,116,149)(H3,111,117,150)/t63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-/m0/s1
2.1.3 InChI Key
JJVZSYKFCOBILL-MKMRYRNGSA-N
2.1.4 Canonical SMILES
C1CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC5=CC=CC=C5C=C4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)NC(CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O
2.1.5 Isomeric SMILES
C1C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC5=CC=CC=C5C=C4)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O
2.2 Other Identifiers
2.2.1 UNII
DA9G065962
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Bl-8040

2. 4f-benzoyl-tn14003

3. Motixafortide [usan]

4. Tf14016

5. Bkt140

6. Bkt 140

7. Bkt-140

8. 664334-36-5

9. Da9g065962

10. Tf 14016

11. Tf-14016

12. Motixafortida

13. Motixafortidum

14. Motixafortide [inn]

15. Motixafortide [who-dd]

16. Unii-da9g065962

17. Gtpl10679

18. Chebi:145536

19. 4f-benzoyl-tn-14003

20. Bl8040

21. Who 10935

22. Bl 8040

23. Db14939

24. Q27276305

25. L-argininamide, N2-(4-fluorobenzoyl)-l-arginyl-l-arginyl-3-(2-naphthalenyl)-l-alanyl-l-cysteinyl-l-tyrosyl-n5-(aminocarbonyl)-l-ornithyl-l-lysyl-d-lysyl-l-prolyl-l-tyrosyl-l-arginyl-n5-(aminocarbonyl)-l-ornithyl-l-cysteinyl-, Cyclic (4->13)-disulfide

26. N-(4-fluoro-benzoyl)-l-arginyl-l-arginyl-(l-3-(naphthyl)alanyl)-l-cysteinyl-l-tyrosyl-l-citrullinyl-l-lysyl-d-lysyl-l-prolyl-l-tyrosyl-l-arginyl-l-citrullinyl-l-cysteinyl-l-arginine Amide,cyclic (4-13)-disulfide

27. S3.4,s3.13-cyclo(n.alpha.-(4-fluorobenzoyl)-l-arginyl-l-arginyl-3-(naphthalen-2-yl)-l-alanyl-l-cysteinyl-l-tyrosyl-n5-carbamoyl-l-ornithyl-l-lysyl-d-lysyl-l-prolyl-l-tyrosyl-larginyl-n5-carbamoyl-l-ornithyl-l-cysteinyl-l-argininamide)

2.4 Create Date
2015-09-16
3 Chemical and Physical Properties
Molecular Weight 2159.5 g/mol
Molecular Formula C97H144FN33O19S2
XLogP3-2.9
Hydrogen Bond Donor Count34
Hydrogen Bond Acceptor Count28
Rotatable Bond Count53
Exact Mass2159.0775248 g/mol
Monoisotopic Mass2158.0741700 g/mol
Topological Polar Surface Area943 Ų
Heavy Atom Count152
Formal Charge0
Complexity4500
Isotope Atom Count0
Defined Atom Stereocenter Count14
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY